Trial Profile
A double-blind, placebo-controlled study of the effect of a TNFα a inhibitor, etanercept (Enbrel), on microglial activation in amyloid PET positive patients with mild cognitive impairment due to Alzheimer's disease-intermediate likelihood
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Therapeutic Use
- Acronyms INMiND02
- 31 Jul 2020 Results presented at the Alzheimer's Association International Conference 2020
- 01 Dec 2017 Status changed from active, no longer recruiting to completed.
- 02 Sep 2015 Status changed from not yet recruiting to recruiting as reported by ISRCTN: Current Controlled Trials.